ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1180 • 2018 ACR/ARHP Annual Meeting

    The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Commercially-Insured Population in the United States Stratified By Disease Severity

    Ann E. Clarke1, Shaum Kabadi2, Emily Durden3, Isabelle Winer3, Kirstin Bacani2, Karen Costenbader4 and Jinoos Yazdany5, 1Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2AstraZeneca, Gaithersburg, MD, 3Truven Health Analytics an IBM Company, Ann Arbor, MI, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 5University of California, San Francisco, San Francisco, CA

    Background/Purpose: Most currently available estimates of the economic burden of SLE in the US do not consider disease severity. The purpose of this study is…
  • Abstract Number: 1181 • 2018 ACR/ARHP Annual Meeting

    Hydroxychloroquine: Do We All See Eye to Eye? a Single-Site Analysis of Hydroxychloroquine Dosing Compared to 2016 American Academy of Ophthalmology Guidelines

    Vaneet K. Sandhu1, Noopur Goel2 and Jamileh Hanna2, 1Division of Rheumatology, Loma Linda University, Loma Linda, CA, 2Loma Linda University, Loma Linda, CA

    Background/Purpose: Hydroxychloroquine is universally recommended to treat patients with SLE, stressing the importance of appropriate dosing. The 2016 American Academy of Ophthalmology (AAO) guidelines recommend…
  • Abstract Number: 1182 • 2018 ACR/ARHP Annual Meeting

    The Disproportionate High Risk of Re-Fracture after Osteoporotic Treatment in Patients with Autoimmune Diseases

    Wen-Nan Huang1, Yi-Ming Chen1, Wei-Ting Hung2, Yu-Wan Liao3 and Yi-Hsing Chen1, 1Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, 2Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, 3Taichung Veterans General Hospital, Taichung, Taiwan

    Background/Purpose: Patients with autoimmune diseases are associated with an increased risk of osteoporotic fracture. Anti-osteoporotic treatment could diminish re-fracture rates in post-menopause women. However, treatment…
  • Abstract Number: 1183 • 2018 ACR/ARHP Annual Meeting

    The Distribution of Insurance in a Population-Based Cohort of SLE: Georgians Organized Against Lupus Cohort, 2012-2016

    S. Sam Lim1, Charles G. Helmick2, Gaobin Bao3, Caroline Gordon4, Jennifer M. Hootman2 and Cristina Drenkard5, 1Emory University School of Medicine, Atlanta, GA, 2Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, 3Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 4Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 5Medicine/Rheumatology, Emory University, Atlanta, GA

    Background/Purpose: Having health insurance coverage is important for people with chronic conditions. Those with systemic lupus erythematosus (SLE) are particularly vulnerable given the disproportionate impact…
  • Abstract Number: 1184 • 2018 ACR/ARHP Annual Meeting

    Withdrawn

    Withdrawn
  • Abstract Number: 1185 • 2018 ACR/ARHP Annual Meeting

    Cause and Rate of Hospitalization of Lupus Patients

    Reem Aldarmaki1, Hiba Khogali2 and Ali AlDhanhani3, 1Medical Student, UAEU, College of Medicine, Al Ain, United Arab Emirates, 2Rheumatologist, Tawam hospital, SEHA, Al Ain, United Arab Emirates, 3Assistant professor, UAEU, College of Medicine, Al Ain, United Arab Emirates

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multiorgan disease that is associated with significant morbidity and mortality. Literature suggests improvement in the survival rates…
  • Abstract Number: 1186 • 2018 ACR/ARHP Annual Meeting

    Comparison of Biologic Discontinuation in Patients with Elderly-Onset Vs Younger-Onset Rheumatoid Arthritis

    Michael Richter1, Eric L. Matteson2, John M. Davis III2, Sara J. Achenbach3 and Cynthia S. Crowson3, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN

    Background/Purpose: Several studies have suggested that patients with elderly-onset rheumatoid arthritis (EORA) receive biologic treatments less frequently than patients with younger-onset RA (YORA). This has…
  • Abstract Number: 1187 • 2018 ACR/ARHP Annual Meeting

    Impact of a Nurse-Led Program of Patient Self-Assessment and Self-Management Axial Spondyloarthritis: Results of a Prospective, Multicentre, Randomized, Controlled Trial

    Anna Molto1, Adrien Etcheto2, Serge Poiraudeau3, Laure Gossec4, Pascal Claudepierre5, Martin Soubrier6, Françoise Fayet7, Daniel Wendling8, Philippe Gaudin9, Emmanuelle Dernis10, Sandrine Guis11, Sophie Pouplin12, Adeline Ruyssen-Witrand13 and Maxime Dougados14, 1Rheumatology, Cochin Hospital, Paris, France, 2Department of Rheumatology, Paris Descartes University, Hôpital Cochin, Paris, France, 3Univ. Paris Descartes, PRES Sorbonne Paris, INSERM UMR-S 1153 et Institut fédératif de recherche sur le handicap, Paris, France, Paris, France, 4Rheumatology, Pitié Salpêtrière Hospital, Paris, France, 5Universite Paris Est Creteil, Paris, France, 6Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 7CHU Gabriel Montpied, Clermont Ferrand, France, 8Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, 9Grenoble University Hospital, France, Grenoble, France, 10Service de Rhumatologie, CH du Mans, Le Mans, France, 11Rheumatology Department, CHU, Marseile, France, 12Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 13Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, 14Paris Descartes University, Hôpital Cochin, Paris, France

    Background/Purpose: The objective of this study was to evaluate the impact of a nurse- led program of self-management and self-assessment for disease activity program in…
  • Abstract Number: 1188 • 2018 ACR/ARHP Annual Meeting

    Are Residents Choosing Wisely? Analysis of Adherence to Recommendations of Ordering Anti-Nuclear Antibody Testing in an Internal Medicine Residency Primary Care Clinic

    Aparna Das, Rajarajan Panneerselvan, Annum Faisal, Jubran Rind and Rima Shah, Internal medicine, Michigan state university, grand rapids, MI

    Background/Purpose: A positive anti-nuclear antibody (ANA) is considered very useful for the diagnosis of SLE and systemic sclerosis, and somewhat useful for the diagnosis of…
  • Abstract Number: 1189 • 2018 ACR/ARHP Annual Meeting

    Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean Perspective

    Dam Kim1, Hyojin Kim2, Seongha Cho2 and Min-Chan Park1, 1Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of (South), 2Patient Access Team, Novartis Korea, Seoul, Korea, Republic of (South)

    Secukinumab versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean PerspectiveDam Kim1, Hyojin Kim2, SeongHa Cho2, Min-Chan Park11Division of…
  • Abstract Number: 1190 • 2018 ACR/ARHP Annual Meeting

    Use of Biologic Drugs and Adverse Events in Patients with Rheumatic Disease: DATA from the Mexican Biologics Registry

    Daniel Xibille-Friedmann1, Sandra Miriam Carrillo -Vazquez2, Sandra Sicsik Ayala3, Fedra Irazoque-Palazuelos4, Azucena Ramos-Sanchez5, Sergio Duran-Barragan6, Miguel A Saavedra7, Leonor Barile8 and Guadalupe Olvera9, 1Research and Training Department, Servicios de Salud de Morelos, Cuernavaca, Mexico, 2Rheumatology, Hospital 1 de Octubre ISSSTE, Mexico City, Mexico, 3Rheumatology, UMAE 71 IMSS, Torreon, Mexico, Torreon, Mexico, 4Rheumatology Department, CMN 20 de Noviembre ISSSTE,, CDMX, Mexico, 5Rheumatology, CMN NE 25 IMSS, Monterrey, Mexico, 6Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, 7Novartis Farmaceutica, Calz de Tlaplan 1779, Mexico, Mexico, 8Hospital Ángeles del Pedregal, Mexico, Mexico, 9Research Department, Colegio Mexicano de Reumatologia, Mexico City, Mexico

    Background/Purpose: National registries of biologic drugs have proven to be valuable tools in following patients with rheumatic disease and some outcomes in real-life situations. The…
  • Abstract Number: 1191 • 2018 ACR/ARHP Annual Meeting

    The Importance of Quantitative Assessment of Joint/Organ Damage and Patient Distress in Addition to Inflammatory Activity in Routine Clinical Care

    Theodore Pincus, Isabel Castrejón and Joel A. Block, Division of Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Quantitative measures such as laboratory tests and pooled indices have advanced clinical rheumatology care far beyond narrative decisions. These measures generally are directed to…
  • Abstract Number: 1192 • 2018 ACR/ARHP Annual Meeting

    The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares

    Filip van Den Bosch1, Siegfried Wassenberg2, Boulos Haraoui3, Patrick Zueger4, Meijing Wu4, Ivan Lagunes Galindo4 and Andrew Ostor5, 1Ghent University Hospital, Ghent, Belgium, 2Rheumazentrum Ratingen, Ratingen, Germany, 3Université de Montréal, Montreal, QC, Canada, 4AbbVie Inc., North Chicago, IL, 5Cabrini Medical Center, Melbourne, Australia

    Background/Purpose: The AbbVie patient (pt) support program (PSP) is offered to pts prescribed adalimumab for RA and other indications. The purpose of this analysis was…
  • Abstract Number: 1193 • 2018 ACR/ARHP Annual Meeting

    Consensus Statements on Scanning Conventions and Documentation in Musculoskeletal Ultrasound

    Karina Torralba1, Midori Jane Nishio2, Ralf G. Thiele3, Robert Fairchild4, Kristal Choi5, Lorena Salto5, Amy C. Cannella6 and Eugene Kissin7, 1Loma Linda University Medical Center, Loma Linda, CA, 2John Muir Hospital, Walnut Creek, CA, 3Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, 4Stanford University, Palo Alto, CA, 5Loma Linda University, Loma Linda, CA, 6Section of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 7Boston University, Boston, MA

    Background/Purpose: Point-of-care (POC) musculoskeletal ultrasound (MSUS) over the past decade has increasingly been adopted to evaluate patients with rheumatic diseases. In 2011, a group of…
  • Abstract Number: 1194 • 2018 ACR/ARHP Annual Meeting

    The Physiological Changes of the Enthesis in Response to Age, Body Mass Index and Physical Activity: An Ultrasound Study in Healthy People

    Dilek Solmaz1, Sibel Bakirci2, Wilson Stephenson3, Lihi Eder4, Johannes Roth5 and Sibel Zehra Aydın6, 1Rheumatology, University of Ottawa, Ottawa, ON, Canada, 279 Cresthaven Drive, University of Ottawa, Ottawa, ON, Canada, 3Internal Medicine, University of Ottawa, Ottawa, ON, Canada, 4Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, 5Pediatric Rheumatology, Children's Hospital Eastern Ontario, Ottawa, ON, Canada, 6University of Ottawa, Ottawa, ON, Canada

    Background/Purpose: Entheses are exposed to biomechanical stress throughout life and sonographic entheseal abnormalities may not reflect an underlying inflammatory arthritis in all cases. In this…
  • « Previous Page
  • 1
  • …
  • 1263
  • 1264
  • 1265
  • 1266
  • 1267
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology